Carmat SAS is an innovative medtech start-up created and financed by Truffle Capital, EADS (http://www.eads.com) and the Fondation Alain Carpentier, with additional funding from the French state innovation agency OSEO (http://www.oseo.fr/).
- The company has been spun out of the collaboration between the renowned surgeon Professor Carpentier and EADS on implementation of biomaterials and cutting-edge technologies in the construction of an artificial heart. Carmat intends to market a fully implantable artificial heart that will be able to provide renewed hope and quality of life to the hundreds of thousands of patients suffering in the aftermath of a massive heart attack or with late-stage heart failure and for whom standard drug therapy, ventricular assistance and/or a heart transplant have failed or are not possible. The preliminary animal trials and lab test performed with the Carmat artificial heart have generated interest from the French and worldwide medical community and health authorities.
- Following a €7 million first round of financing led by Truffle Capital, Carmat will seek additional international equity investments in the years to come. OSEO has just awarded the company €33 million in grants-in-aid and loans - the largest amount of funding ever awarded to a start-up by OSEO